Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587759 | 0.83 | CDC25B (0.33) | CDC7MAPKAPK2MKNK1CDC25B | |
| SCHEMBL1190111 | 0.75 | GRM5 (0.36) | MAP4K1 | |
| SCHEMBL3063384 | 0.75 | FABP6 (0.44) | ALPLFABP6GSK3BNTRK1 | |
| SCHEMBL3394900 | 0.74 | ALPL (0.41) | ALPLFABP6NTRK1MAP4K1JAK2 | |
| SCHEMBL21291859 | 0.74 | ALPL (0.46) | ALPLFABP6MAPKAPK2GSK3BNTRK1 | |
| SCHEMBL21333463 | 0.74 | ALPL (0.46) | ALPLFABP6GSK3BNTRK1ROS1 | |
| SCHEMBL30229269 | 0.73 | FABP6 (0.40) | FABP6GSK3BNTRK1KDM4ECDC25B | |
| SCHEMBL19553234 | 0.72 | DAPK3 (0.47) | CDC7MAPKAPK2GSK3BMKNK1CDC25B | |
| SCHEMBL3046656 | 0.70 | CDC7 (0.43) | CDC7MAPKAPK2GSK3BMKNK1 | |
| SCHEMBL29937493 | 0.70 | CDC7 (0.43) | CDC7MAPKAPK2GSK3BMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | ALPL 3252/4885FABP6 392/4885CDC7 2718/4885 |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | ALPL 1679/4885FABP6 477/4885CDC7 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.